The Fly | ELUT

Proprietary Tissue Processing Platforms: Aziyo Biologics utilizes advanced and proprietary processing technologies that maintain the structural and biological integrity of tissues, leading to enhanced biocompatibility and performance of their regenerative medicine products.

Diverse Biologics Product Portfolio: The company offers a broad range of biologic implants across multiple large surgical markets, including soft tissue reconstruction, spinal fusion, and cardiac rhythm management, diversifying revenue streams and market reach.

Established Commercial Infrastructure: Aziyo possesses a developed sales and marketing apparatus, including direct sales teams and strategic distribution partnerships, facilitating market access and adoption of their products by healthcare providers.

Regulatory Approval and Compliance Risks: Our products require extensive regulatory approval, and failure to obtain or maintain these approvals, or comply with complex regulations, could severely impact our business.

Commercialization and Market Adoption Risks: Our success depends on the widespread adoption and successful commercialization of our products, which may not occur due to market competition, physician acceptance, or other factors.

Financial Performance and Funding Risks: We have a history of operating losses and may not achieve or maintain profitability, requiring us to raise additional capital in the future, which may not be available on favorable terms or at all.